Evaluation of protein biomarkers of prostate cancer aggressiveness
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Prognostic multibiomarker signatures in prostate cancer (PCa) may improve patient management and provide a bridge for developing novel therapeutics and imaging methods. Our objective was to evaluate the association between expression of 33 candidate protein biomarkers and time to biochemical failure (BF) after prostatectomy. METHODS: PCa tissue microarrays were constructed representing 160 patients for whom clinicopathologic features and follow-up data after surgery were available. Immunohistochemistry for each of 33 proteins was quantified using automated digital pathology techniques. Relationships between clinicopathologic features, staining intensity, and time to BF were assessed. Predictive modeling using multiple imputed datasets was performed to identify the top biomarker candidates. RESULTS: In univariate analyses, lymph node positivity, surgical margin positivity, non-localized tumor, age at prostatectomy, and biomarkers CCND1, HMMR, IGF1, MKI67, SIAH2, and SMAD4 in malignant epithelium were significantly associated with time to BF. HMMR, IGF1, and SMAD4 remained significantly associated with BF after adjusting for clinicopathologic features while additional associations were observed for HOXC6 and MAP4K4 following adjustment. In multibiomarker predictive models, 3 proteins including HMMR, SIAH2, and SMAD4 were consistently represented among the top 2, 3, 4, and 5 most predictive biomarkers, and a signature comprised of these proteins best predicted BF at 3 and 5 years. CONCLUSIONS: This study provides rationale for investigation of HMMR, HOXC6, IGF1, MAP4K4, SIAH2, and SMAD4 as biomarkers of PCa aggressiveness in larger cohorts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fully conditional specification in multivariate imputation
Van Buuren, S., Brand, J. P. L., Groothuis-Oudshoorn, C. G. M., & Rubin, D. B. (2006) · Journal of Statistical Computation and Simulation · doi:10.1080/10629360600810434 · Cited by 1,217
Glinsky, G. V., Berezovska, O., & Glinskii, A. B. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23412 · Cited by 916 · cited 2×
“Other groups have developed multi-biomarker signatures of PCa aggressiveness using gene expression profiling as a method for biomarker discovery; these studies have surprisingly little overlap be-tween gene sets [6,9,10,13,15-18].”
Yu, Y. P., Landsittel, D., Jing, L., Nelson, J., Ren, B., Liu, L., McDonald, C., Thomas, R., Dhir, R., Finkelstein, S., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.158 · Cited by 758
Cited by
Hypoxia and Selective Autophagy in Cancer Development and Therapy
Daskalaki, I., Gkikas, I., & Tavernarakis, N. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00104 · Cited by 188
Emerging proteomics biomarkers and prostate cancer burden in Africa
Adeola, H. A., Blackburn, J. M., Rebbeck, T. R., & Zerbini, L. F. (2017) · Oncotarget · doi:10.18632/oncotarget.16568 · Cited by 26
Minchenko (2015) · doi:10.15407/ubj87.02.076 · Cited by 17
Metadata
- Authors
- Rizzardi, A. E., Rosener, N. K., Koopmeiners, J. S., Isaksson Vogel, R., Metzger, G. J., Forster, C. L., Marston, L. O., Tiffany, J. R., McCarthy, J. B., Turley, E. A., Warlick, C. A., Henriksen, J. C., & Schmechel, S. C.
- Venue
- BMC Cancer
- Published
- 2014-04-05
- Volume
- 14
- Issue
- 1
- Pages
- 244-244
- ISSN
- 1471-2407 (ISSN-L)
- OpenAlex
- W2118599376
- Cited by
- 55
- References
- 3
- FWCI
- 5.33
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluation of protein biomarkers of prostate cancer aggressiveness. https://app.cochat.ai/papers/10.1186/1471-2407-14-244
- The paper
- Rizzardi, A. E., Rosener, N. K., Koopmeiners, J. S., Isaksson Vogel, R., Metzger, G. J., Forster, C. L., Marston, L. O., Tiffany, J. R., McCarthy, J. B., Turley, E. A., Warlick, C. A., Henriksen, J. C., & Schmechel, S. C. (2014). Evaluation of protein biomarkers of prostate cancer aggressiveness. BMC Cancer. https://doi.org/10.1186/1471-2407-14-244
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.